|
市場調査レポート
商品コード
1384827
高気圧酸素治療装置の世界市場規模、シェア、産業動向分析レポート:用途別、製品別、地域別展望と予測、2023年~2030年Global Hyperbaric Oxygen Therapy Devices Market Size, Share & Industry Trends Analysis Report By Application, By Product, By Regional Outlook and Forecast, 2023 - 2030 |
||||||
|
高気圧酸素治療装置の世界市場規模、シェア、産業動向分析レポート:用途別、製品別、地域別展望と予測、2023年~2030年 |
出版日: 2023年10月31日
発行: KBV Research
ページ情報: 英文 277 Pages
納期: 即納可能
![]() |
高気圧酸素治療装置市場規模は、予測期間中にCAGR 5.1%で成長し、2030年には47億米ドルに達すると予測されます。2022年の市場規模は1,13,114台で、成長率は4.9%となっています(2019-2022年)。
ただし、バロトラウマとは圧力の変化によって生じる創傷を指します。HBOT中、圧力の変化は耳、副鼻腔、肺に影響を与える可能性があります。患者は耳の痛み、副鼻腔のうっ血、肺の損傷を経験することがあります。このリスクを軽減するため、患者は注意深く選別され、安全対策が講じられているが、圧外傷の可能性があるため、HBOTを受けようとしない人もいます。高濃度の酸素に長時間さらされると、酸素中毒を引き起こす可能性があり、肺や中枢神経系の問題を引き起こすことがあります。HBOTセッションは、酸素中毒のリスクを最小限に抑えるため、注意深くモニターされます。状況によっては、健康保険がHBOTをカバーしないこともあり、自己負担費用を支払えない患者にとっては、HBOTが利用しにくくなります。HBOTとそのリスクに関する誤った情報や誤解が、潜在的な患者の足を引っ張ることもあります。上記の側面は市場成長の妨げとなります。
COVID-19は高気圧酸素治療装置市場にマイナスの影響を与えました。他の多くの産業と同様、パンデミックの初期段階で、HBOT機器を含む医療機器の製造とサプライチェーンが混乱しました。施錠、移動制限、サプライチェーンの中断は、これらの機器の生産と流通に影響を与えました。このため、ただちに生命を脅かすとは考えられない症状に対するHBOT機器の使用は一時的に減少しました。COVID-19関連合併症の治療におけるHBOTの有効性を探る臨床試験や研究が開始されました。しかし、市場はパンデミック後に急速に回復し、今後数年で大きく拡大することが予想されます。
用途別展望
用途別に見ると、市場は創傷治癒、減圧症、感染症治療、ガス塞栓症、その他に細分化されます。減圧症分野は、2022年の市場で大きな収益シェアを獲得しました。HBOTは、「潜水病」としても知られる減圧症(DCS)に対する非常に効果的な治療法です。減圧症は、スキューバダイバーや水中作業員が高圧環境(水中など)から低圧環境(水面)に急速に上昇しすぎた場合に発生します。この急激な圧力変化によって、体内の組織や血流に窒素の気泡が生じ、関節痛、胸痛、呼吸困難、神経症状など、さまざまな症状を引き起こします。
製品の展望
製品別では、市場はモノプレイス型、マルチプレイス型、局所型に区分されます。2022年には、モノプレース・セグメントが最大の収益シェアで市場を独占しました。モノプレイスシステムは、使い勝手がよく、病院へのガス供給が最小限で済むため、採用率が高く、商業的に利用しやすいことが、市場シェア拡大の大きな要因となっています。最も普及している高気圧チャンバーは、ETCのBARA-MED、BARA-MEDXD、BARA-MED Select、Pan-America Hyperbarics, Inc.のPAH-S1-3800高気圧チャンバーとPAH-S1高気圧チャンバーです。
地域別展望
地域別に見ると、市場は北米、欧州、アジア太平洋、LAMEAで分析されます。2022年には、北米地域が市場で最も高い収益シェアを記録しました。同地域では人口が増加しており、高気圧酸素治療に対する需要と創傷回復治療の必要性が高まっています。消費者の可処分所得が増加しているため、技術的に進歩した医療治療や療法を求めるようになっています。2023年2月、米国のマウイ・メモリアル・メディカル・センターは、治癒しない創傷に包括的なアプローチを提供する高気圧酸素治療を備えた創傷治療クリニックを開設しました。
The Global Hyperbaric Oxygen Therapy Devices Market size is expected to reach $4.7 billion by 2030, rising at a market growth of 5.1% CAGR during the forecast period. In the year 2022, the market attained a volume of 1,13,114 units, experiencing a growth of 4.9% (2019-2022).
HBOT can be used as an adjunctive treatment for certain infections, particularly those caused by anaerobic bacteria or those that benefit from increased oxygen levels to enhance the body's natural defense mechanisms. Consequently, the infection treatment segment experienced $351.9 million revenue in the market in 2022. Anaerobic bacteria are microorganisms that thrive in low-oxygen environments. HBOT exposes the body to high oxygen concentrations, creating an oxygen-rich environment inhospitable to many anaerobic pathogens. This inhibits the growth and replication of these bacteria. HBOT is administered in specialized hyperbaric chambers under the supervision of trained medical personnel. Some of the factors impacting the market are growing demand for next generation multiplace chambers, rising prevalence of chronic diseases and side effects and complications associated with HBOT.
Next generation multiplace chambers are designed with a focus on patient comfort. They often offer more spacious interiors with better seating arrangements, lighting, and entertainment options. Enhanced comfort can encourage patients to undergo longer and more effective HBOT sessions. Multiplace chambers can accommodate multiple patients simultaneously, making them a more cost-effective and efficient option for healthcare facilities. This increased capacity can reduce waiting times for patients and improve accessibility to HBOT therapy. The rising number of chronic diseases has significantly driven the hyperbaric oxygen therapy devices market growth. Chronic diseases are long-term medical conditions that often require ongoing treatment and care. HBOT has proven effective in managing and treating various chronic diseases and associated complications, increasing adoption. Diabetes is an ordinary chronic disease that can lead to difficulties such as diabetic foot ulcers. HBOT is a recognized treatment for diabetic foot ulcers, as it promotes wound healing and reduces the risk of amputation. Therefore, as healthcare providers and patients recognize the advantages of HBOT in managing and improving the quality of life for those with chronic diseases, the market for hyperbaric oxygen therapy devices is expected to continue to rise.
However, Barotrauma refers to wounds caused by changes in pressure. During HBOT, changes in pressure can affect the ears, sinuses, and lungs. Patients may experience ear pain, sinus congestion, or lung injuries. In order to mitigate this risk, patients are carefully screened, and safety measures are put in place, but the potential for barotrauma can deter some individuals from seeking HBOT. Prolonged exposure to high oxygen levels can lead to oxygen toxicity, which can cause lung and central nervous system problems. HBOT sessions are carefully monitored to minimize the risk of oxygen toxicity. In some circumstances, health insurance may not cover HBOT, making it less accessible to patients who cannot afford the out-of-pocket costs. Misinformation or misconceptions about HBOT and its risks can deter potential patients. The abovementioned aspects will hamper the market growth.
COVID-19 had a negative impact on the hyperbaric oxygen therapy devices market. Like many other industries, the manufacturing and supply chain for medical devices, including HBOT devices, were disrupted during the early stages of the pandemic. Lockdowns, restrictions on movement, and supply chain interruptions affected the production and distribution of these devices. This led to a temporary decline in the use of HBOT devices for conditions that were not considered immediately life-threatening. Clinical trials and studies exploring the efficacy of HBOT in treating COVID-19-related complications were initiated. However, the market witnessed a speedy recovery after the pandemic and will expand significantly in the coming years.
Application Outlook
Based on application, the market is fragmented into wound healing, decompression sickness, infection treatment, gas embolism, and others. The decompression sickness segment garnered a significant revenue share in the market in 2022. HBOT is a highly effective treatment for decompression sickness (DCS), also known as "the bends." DCS occurs when a scuba diver or underwater worker ascends too quickly from a high-pressure environment (such as underwater) to a lower-pressure environment (the surface). This rapid change in pressure can cause nitrogen bubbles in the body's tissues and bloodstream, leading to various symptoms, including joint pain, chest pain, breathing difficulties, and neurological symptoms.
Product Outlook
On the basis of product, the market is segmented into monoplace, multiplace, and topical. In 2022, the monoplace segment dominated the market with the maximum revenue share. The substantial adoption rate and commercial accessibility of monoplace systems, due to their user-friendliness and minimal need for hospital gas supply, are significant contributors to its larger market share. The most popular hyperbaric chambers are BARA-MED, BARA-MEDXD, and BARA-MED Select by ETC; PAH-S1-3800 Hyperbaric Chamber and PAH-S1 Hyperbaric Chamber by Pan-America Hyperbarics, Inc.
Regional Outlook
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region registered the highest revenue share in the market. The region's growing population has fueled the region's demand for hyperbaric oxygen therapy and the need for wound recovery treatment. Consumers' increasing disposable income has prompted them to seek technologically advanced medical treatments and therapies. In February of 2023, the Maui Memorial Medical Center in the United States opened a wound care clinic with hyperbaric oxygen therapy, which provides a comprehensive approach to non-healing wounds.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Fink Engineering Pty Ltd, Environmental Tectonics Corporation, HAUX-LIFE-SUPPORT GmbH, Gulf Coast Hyperbarics, Inc., HearMEC Co., Ltd., Hyperbaric SAC, Sechrist Industries, Inc, SOS Group GBR Ltd., Perry Baromedical Corporation and SMP Ltd.
Market Segments covered in the Report:
By Application (Volume, Unit, USD Million, 2019-30)
By Product (Volume, Unit, USD Million, 2019-30)
By Geography (Volume, Unit, USD Million, 2019-30)
Companies Profiled
Unique Offerings from KBV Research